Sjögren's disease
Every trial of Tenofovir Alafenamide, Entecavir and Ianalumab across our registers →
Change from baseline in SSSD oral dryness score at Week 52
Change from baseline in SSSD summary score at Week 52, Change from baseline in ESSPRI score at Week 52, Change from baseline in sSF at Week 52, Change from baseline in PaGA NRS score at Week 52, Achieving SSSD response at week 52, Achieving ESSPRI response at week 52, Change from baseline in SSSD eye dryness score at Week 52., Change from baseline in FACIT- Fatigue score at Week 52, Change from baseline in SRQoL score at Week 52, Incidence of treatment-emergent adverse events (TEAEs)/serious adverse events (SAEs) •Routine hematology and clinical chemistry laboratory test results • Vital signs
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2025-522271-29-00 on CTIS ↗ ← All trials in the EU